Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

Lawrence J. Green, MD LLC, Rockville

RM Medical Research, Inc., Miami Lakes

Allervie Clinical Research, Birmingham

Optima Research Boardman, Boardman

Indiana Clinical Trials Center, Plainfield

Revival Research Institute, LLC, Troy

J&S Studies, Inc., College Station

Jordan Valley Dermatology Center, South Jordan

Dermatology Specialists of Spokane, Spokane

Innovaderm Research Inc., Montreal